IP Library › Granted Patent US 12,635,718
Granted Patent B2
US 12,635,718 · App. 17/637,944 · Granted May 26, 2026

Flavanone derivatives and their use as sweetness enhancers

Inventors: Eric Frerot (Satigny, CH); Tim Vernet (Satigny, CH); Yves Lottaz (Satigny, CH); Kerstin Steiner (Satigny, CH); Priti Jha (Plainsboro, NJ); Dattatreya Banavara (Plainsboro, NJ)
A23L27/88A23L2/60A23L27/30A23L27/84A23L27/86C07D311/62A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,635,718
App. No.
17/637,944
Granted
May 26, 2026
Kind
B2
Abstract

The present disclosure generally provides a class of flavanone derivatives and their use as sweetness enhancers. In some aspects, the disclosure provides certain compositions that include such flavanone derivatives, such as compositions that include such flavanone derivatives and one or more other sweeteners. In some other aspects, the disclosure provides methods of reducing the caloric content of a sweetened article, such as a sweetened food or beverage product.

Claims (16)

1 . A method of enhancing a sweet taste, or reducing a bitter taste, of an ingestible composition, the method comprising introducing a combination of flavor-modifying compounds to the ingestible composition; wherein the ingestible composition is free of any steviol glycosides; and wherein the combination of flavor-modifying compounds comprises a compound of formula (Ib)

or a salt thereof; and

or a salt thereof;

wherein the combination of flavor-modifying compounds is present in the ingestible composition at a concentration ranging from 1 ppm to 50 ppm by weight of the ingestible composition; and

wherein the ingestible composition comprises a sweetener selected from the group consisting of sucrose, fructose, glucose, and any combination thereof;

wherein the combination of flavor-modifying compounds further comprises

or a salt thereof.

2 . The method of claim 1 , wherein the combination of flavor-modifying compounds further comprises

or a salt thereof.

3 . An ingestible composition, which comprises a combination of flavor-modifying compounds and a sweetener selected from the group consisting of sucrose, fructose, glucose, and any combination thereof; wherein the combination of flavor-modifying compounds is present at a concentration ranging from 1 ppm to 50 ppm by weight of the ingestible composition, wherein the ingestible composition is free of any steviol glycosides, and wherein the flavor-modifying compound comprises a compound of formula (Ib)

or a salt thereof; and

or a salt thereof;

wherein the combination of flavor-modifying compounds further comprises

or a salt thereof.

4 . The composition of claim 3 , wherein the combination of flavor-modifying compounds further comprises

or a salt thereof.

Priority Claims (1)
EP 19200701 · Oct 1, 2019 · regional
Continuity (2)
Provisional Application 62896017 · Sep 5, 2019
Related Publication 20220273012A1 · Sep 1, 2022
References Cited (31)
US 6468576B1 · Sher et al. · 2002 [cited by applicant]
US 8076491B2 · Karanewsky et al. · 2011 [cited by applicant]
US 8735081B2 · Li et al. · 2014 [cited by applicant]
US 8815956B2 · Tachdjian et al. · 2014 [cited by applicant]
US 8877922B2 · Tachdjian et al. · 2014 [cited by applicant]
US 8968708B2 · Tachdjian et al. · 2015 [cited by applicant]
US 9000051B2 · Feltin et al. · 2015 [cited by applicant]
US 9000054B2 · Tachdjian et al. · 2015 [cited by applicant]
US 9247759B2 · Karanewsky et al. · 2016 [cited by applicant]
US 9394287B2 · Priest et al. · 2016 [cited by applicant]
US 9834544B2 · Tachdjian et al. · 2017 [cited by applicant]
US 10421727B2 · Chumakova et al. · 2019 [cited by applicant]
US 11357246B2 · Patron et al. · 2022 [cited by applicant]
US 20070059422A1 · Robbins · 2007 [cited by applicant]
US 20090111834A1 · Tachdjian · 2009 [cited by applicant]
US 20100292175A1 · Wessjohann et al. · 2010 [cited by applicant]
US 20110230502A1 · Tachdjian et al. · 2011 [cited by applicant]
US 20120088796A1 · Karanewsky · 2012 [cited by applicant]
US 20130216692A1 · Sabater et al. · 2013 [cited by applicant]
US 20140342078A1 · Hayes · 2014 [cited by examiner]
US 20140370177A1 · Jia et al. · 2014 [cited by applicant]
US 20150050410A1 · Luo et al. · 2015 [cited by applicant]
US 20150335604A1 · Moshrefi · 2015 [cited by examiner]
CN 101528059 · 2009 [cited by applicant]
CN 104540396 · 2015 [cited by applicant]
WO 8808256 · 1988 [cited by applicant]
WO WO12146584 · 2012 [cited by applicant]
WO WO14153000 · 2014 [cited by applicant]
Apollinaire et al., vol. Nat. Prod. Lett., vol. 9, pp. 33-37 (1996). [cited by applicant]
Nanayakkara et al., J. Med. Chem., vol. 31, pp. 1250-1253 (1988). [cited by applicant]
Int'l Search Report & Written Opinion of Int'l Search Authority, PCT App. No. PCT/EP2020/074497, dated Jan. 13, 2021. [cited by applicant]